Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy

R O'Hanlon, A Grasso, M Roughton, JC Moon, S Clark, R Wage, J Webb, M Kulkarni, D Dawson, L Sulaibeekh, B Chandrasekaran, C Bucciarelli-Ducci, F Pasquale, MR Cowie, WJ McKenna, MN Sheppard, PM Elliott, DJ Pennell, SK Prasad

Research output: Contribution to journalArticle (Academic Journal)

555 Citations (Scopus)

Abstract

OBJECTIVES: We investigated the significance of fibrosis detected by late gadolinium enhancement cardiovascular magnetic resonance for the prediction of major clinical events in hypertrophic cardiomyopathy (HCM). BACKGROUND: The role of myocardial fibrosis in the prediction of sudden death and heart failure in HCM is unclear with a lack of prospective data. METHODS: We assessed the presence and amount of myocardial fibrosis in HCM patients and prospectively followed them for the development of morbidity and mortality in patients over 3.1 +/- 1.7 years. RESULTS: Of 217 consecutive HCM patients, 136 (63%) showed fibrosis. Thirty-four of the 136 patients (25%) in the fibrosis group but only 6 of 81 (7.4%) patients without fibrosis reached the combined primary end point of cardiovascular death, unplanned cardiovascular admission, sustained ventricular tachycardia or ventricular fibrillation, or appropriate implantable cardioverter-defibrillator discharge (hazard ratio [HR]: 3.4, p = 0.006). In the fibrosis group, overall risk increased with the extent of fibrosis (HR: 1.18/5% increase, p = 0.008). The risk of unplanned heart failure admissions, deterioration to New York Heart Association functional class III or IV, or heart failure-related death was greater in the fibrosis group (HR: 2.5, p = 0.021), and this risk increased as the extent of fibrosis increased (HR: 1.16/5% increase, p = 0.017). All relationships remained significant after multivariate analysis. The extent of fibrosis and nonsustained ventricular tachycardia were univariate predictors for arrhythmic end points (sustained ventricular tachycardia or ventricular fibrillation, appropriate implantable cardioverter-defibrillator discharge, sudden cardiac death) (HR: 1.30, p = 0.014). Nonsustained ventricular tachycardia remained an independent predictor of arrhythmic end points after multivariate analysis, but the extent of fibrosis did not. CONCLUSIONS: In patients with HCM, myocardial fibrosis as measured by late gadolinium enhancement cardiovascular magnetic resonance is an independent predictor of adverse outcome. (The Prognostic Significance of Fibrosis Detection in Cardiomyopathy; NCT00930735).
Translated title of the contributionPrognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy
Original languageEnglish
Pages (from-to)867 - 874
Number of pages8
JournalJournal of the American College of Cardiology
Volume56
Issue number11
DOIs
Publication statusPublished - 7 Sep 2010

Bibliographical note

Other: Epub 2010 Jun 25

Fingerprint Dive into the research topics of 'Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy'. Together they form a unique fingerprint.

  • Cite this

    O'Hanlon, R., Grasso, A., Roughton, M., Moon, JC., Clark, S., Wage, R., Webb, J., Kulkarni, M., Dawson, D., Sulaibeekh, L., Chandrasekaran, B., Bucciarelli-Ducci, C., Pasquale, F., Cowie, MR., McKenna, WJ., Sheppard, MN., Elliott, PM., Pennell, DJ., & Prasad, SK. (2010). Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 56(11), 867 - 874. https://doi.org/10.1016/j.jacc.2010.05.010